Seres Therapeutics (MCRB) Upgraded by BidaskClub to Hold

Share on StockTwits

BidaskClub upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a sell rating to a hold rating in a research note issued to investors on Friday morning, BidAskClub reports.

Other analysts have also recently issued reports about the stock. ValuEngine upgraded shares of Seres Therapeutics from a sell rating to a hold rating in a research note on Wednesday, March 27th. HC Wainwright reiterated a buy rating on shares of Seres Therapeutics in a research note on Friday, February 22nd. Zacks Investment Research upgraded shares of Seres Therapeutics from a hold rating to a buy rating and set a $5.50 price objective on the stock in a research report on Friday, January 4th. Cowen restated a buy rating on shares of Seres Therapeutics in a research report on Friday, February 8th. Finally, Oppenheimer restated a buy rating on shares of Seres Therapeutics in a research report on Tuesday, March 19th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $13.06.

NASDAQ MCRB opened at $6.90 on Friday. Seres Therapeutics has a 1 year low of $4.42 and a 1 year high of $9.75. The company has a market capitalization of $283.23 million, a price-to-earnings ratio of -2.84 and a beta of 1.85.

Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Wednesday, March 6th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.67) by $0.15. Seres Therapeutics had a negative net margin of 350.03% and a negative return on equity of 1,584.13%. The business had revenue of $10.63 million for the quarter, compared to analysts’ expectations of $3.78 million. As a group, equities analysts anticipate that Seres Therapeutics will post -1.79 earnings per share for the current fiscal year.

In other news, EVP Thomas Desrosier sold 5,471 shares of the firm’s stock in a transaction on Monday, January 28th. The shares were sold at an average price of $5.75, for a total transaction of $31,458.25. Following the sale, the executive vice president now owns 21,525 shares in the company, valued at approximately $123,768.75. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Eric D. Shaff sold 4,378 shares of the firm’s stock in a transaction on Monday, January 28th. The shares were sold at an average price of $5.75, for a total transaction of $25,173.50. Following the sale, the insider now owns 17,220 shares in the company, valued at approximately $99,015. The disclosure for this sale can be found here. Company insiders own 37.10% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Great West Life Assurance Co. Can bought a new position in shares of Seres Therapeutics during the 4th quarter valued at $30,000. Two Sigma Investments LP bought a new position in shares of Seres Therapeutics during the 4th quarter valued at $82,000. Paloma Partners Management Co bought a new position in shares of Seres Therapeutics during the 3rd quarter valued at $147,000. Jefferies Group LLC grew its holdings in shares of Seres Therapeutics by 75.5% during the 3rd quarter. Jefferies Group LLC now owns 21,424 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 9,215 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Seres Therapeutics by 48.8% during the 4th quarter. Rhumbline Advisers now owns 27,136 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 8,895 shares during the last quarter. Hedge funds and other institutional investors own 77.26% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

Featured Article: Benefits of owning preferred stock

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Brokers Set Expectations for PTC Inc’s Q3 2019 Earnings
Brokers Set Expectations for PTC Inc’s Q3 2019 Earnings
Bodycote  Rating Reiterated by Peel Hunt
Bodycote Rating Reiterated by Peel Hunt
Q3 2019 EPS Estimates for Texas Capital Bancshares Inc Decreased by Analyst
Q3 2019 EPS Estimates for Texas Capital Bancshares Inc Decreased by Analyst
Bellway  Rating Reiterated by Peel Hunt
Bellway Rating Reiterated by Peel Hunt
Applied Materials  Raised to Buy at Goldman Sachs Group
Applied Materials Raised to Buy at Goldman Sachs Group
Xencor  Stock Rating Upgraded by Zacks Investment Research
Xencor Stock Rating Upgraded by Zacks Investment Research


 
© 2006-2019 Zolmax.